Kailera Therapeutics Inc
KLRA
Company Profile
Business description
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Contact
180 Third Avenue
4th Floor
WalthamMA02451
USAT: +1 781 317-0290
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,162.20 | 31.00 | -0.34% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,458.44 | 97.37 | 0.37% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,506.89 | 1,030.99 | 1.76% |
| NZX 50 Index | 12,927.16 | 21.49 | 0.17% |
| S&P 500 | 7,109.14 | 16.92 | -0.24% |
| S&P/ASX 200 | 8,935.10 | 34.40 | -0.38% |
| SSE Composite Index | 4,080.01 | 2.12 | -0.05% |